Background
The first case of HIV infection and AIDS was documented in India in 1986, within five years of the first description of AIDS in North America. The progress of the HIV epidemic was relatively slow, initially. Over the years, the number of HIV infected persons increased and it is a major public health problem now. The estimated number of HIV-1 infected individuals in India was 2.5 million in 2008, which placed India at third place behind South Africa and Nigeria [1].
HIV-1 Genetic Diversity in India
The expanding nature of the HIV-1 epidemic and introduction of Circulating Recombinant Forms (CRFs) and Unique Recombinant Forms (URFs) along with subtypes in addition to the predominant Subtype C, poses a serious clinical and public health concern in India from the very beginning of this pandemic. The genetic analysis of HIV-1 from different parts of India reveals Subtype C strains as a predominant. However, the introduction of other subtypes in high risk group HIV-1 infected patients, primarily female commercial sex workers (CSWs) and intravenous drug users (IDUs), created challenges for therapy and vaccine development programs. A diversified HIV-1 pandemic has been found in different regions of India. The South Indian epidemic is mostly conserved in nature; although, there is the co-existence of Subtypes C, B and CRF08_BC. A group lead by Dr. Udaykumar Ranga at Jawaharlal Nehru Centre for Advance Scientific Research, also found novel B/C recombinant viruses in these populations that are not represented elsewhere. 
Challenges and Possible Solutions
The genetic hypervariability of HIV-1, persistence of latent integrated proviral DNA, differential transmission route, limited utility and relevance of animal models, time consuming and costly clinical trials among motivated volunteer participants, poses unprecedented scientific and organizational challenges to develop vaccine and therapeutic success against this disease. As the transmission routes of several HIV-1 strains have been traced among several neighboring countries, an active scientific coordination is needed between these countries in order to identify the risk groups and geographic locales where new CRFs or multidrug-resistant HIV-1 strains occur and may emerge further [7] . National level vigorous research on HIV-1 genetics in effective collaboration with clinical and basic science researchers is essential for successful and effective therapeutics for all patients suffering from this world's deadly disease.
